Minerva Neurosciences, Inc. focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases.Its lead product candidate is roluperidone for schizophrenia; MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for Parkinson's disease and other neurodegenerative disorders.
